Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
Abstract Aim Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have been seen during treatment. Therefore, the relationships...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7025 |
| _version_ | 1827309278194565120 |
|---|---|
| author | Takahiro Kinami Shinsuke Uchikawa Tomokazu Kawaoka Shintaro Yamasaki Masanari Kosaka Yusuke Johira Shigeki Yano Kei Amioka Kensuke Naruto Kenji Yamaoka Yasutoshi Fujii Hatsue Fujino Takashi Nakahara Atsushi Ono Eisuke Murakami Wataru Okamoto Masami Yamauchi Daiki Miki Masataka Tsuge Shiro Oka |
| author_facet | Takahiro Kinami Shinsuke Uchikawa Tomokazu Kawaoka Shintaro Yamasaki Masanari Kosaka Yusuke Johira Shigeki Yano Kei Amioka Kensuke Naruto Kenji Yamaoka Yasutoshi Fujii Hatsue Fujino Takashi Nakahara Atsushi Ono Eisuke Murakami Wataru Okamoto Masami Yamauchi Daiki Miki Masataka Tsuge Shiro Oka |
| author_sort | Takahiro Kinami |
| collection | DOAJ |
| description | Abstract Aim Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have been seen during treatment. Therefore, the relationships of efficacy, safety, and portal hypertension (PH) were analyzed. Methods A total of 146 patients with u‐HCC and Child‐Pugh Scores of 5–7 received Atezo + Beva. Prophylactic treatment for varices was performed for patients with the risk of rupture of varices before the start of Atezo + Beva. A propensity score‐matched cohort was created to minimize the risk of potential confounders. Efficacy was assessed in 41 propensity score‐matched pairs. AEs were assessed between patients without PH (n = 80) and with PH (n = 66). Results In patients without PH and with PH, median overall survival was 18.4 months and 18.8 months (p = 0.71), and median progression‐free survival was 8.6 months and 5.8 months (p = 0.92), respectively. On the best radiological response evaluation for Response Evaluation Criteria in Solid Tumors, the objective response rate was 31.7% and 26.8% (p = 0.81), respectively. Variceal rupture occurred in three patients with PH, but there were no significant differences in the occurrence of variceal rupture (p = 0.090) and Grade 3–4 AEs between patients without and with PH. Conclusions No significant differences in efficacy and safety were observed with PH. Prophylactic treatment for varices before the start of Atezo + Beva would allow treatment to continue relatively safely. |
| first_indexed | 2024-04-24T19:36:25Z |
| format | Article |
| id | doaj.art-750b5eb5b5f54de5bfbf22b2506451a0 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-24T19:36:25Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-750b5eb5b5f54de5bfbf22b2506451a02024-03-25T13:10:38ZengWileyCancer Medicine2045-76342024-03-01135n/an/a10.1002/cam4.7025Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinomaTakahiro Kinami0Shinsuke Uchikawa1Tomokazu Kawaoka2Shintaro Yamasaki3Masanari Kosaka4Yusuke Johira5Shigeki Yano6Kei Amioka7Kensuke Naruto8Kenji Yamaoka9Yasutoshi Fujii10Hatsue Fujino11Takashi Nakahara12Atsushi Ono13Eisuke Murakami14Wataru Okamoto15Masami Yamauchi16Daiki Miki17Masataka Tsuge18Shiro Oka19Department of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Clinical Oncology Hiroshima University Hospital Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Clinical Oncology Hiroshima University Hospital Hiroshima JapanDepartment of Clinical Oncology Hiroshima University Hospital Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima JapanAbstract Aim Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have been seen during treatment. Therefore, the relationships of efficacy, safety, and portal hypertension (PH) were analyzed. Methods A total of 146 patients with u‐HCC and Child‐Pugh Scores of 5–7 received Atezo + Beva. Prophylactic treatment for varices was performed for patients with the risk of rupture of varices before the start of Atezo + Beva. A propensity score‐matched cohort was created to minimize the risk of potential confounders. Efficacy was assessed in 41 propensity score‐matched pairs. AEs were assessed between patients without PH (n = 80) and with PH (n = 66). Results In patients without PH and with PH, median overall survival was 18.4 months and 18.8 months (p = 0.71), and median progression‐free survival was 8.6 months and 5.8 months (p = 0.92), respectively. On the best radiological response evaluation for Response Evaluation Criteria in Solid Tumors, the objective response rate was 31.7% and 26.8% (p = 0.81), respectively. Variceal rupture occurred in three patients with PH, but there were no significant differences in the occurrence of variceal rupture (p = 0.090) and Grade 3–4 AEs between patients without and with PH. Conclusions No significant differences in efficacy and safety were observed with PH. Prophylactic treatment for varices before the start of Atezo + Beva would allow treatment to continue relatively safely.https://doi.org/10.1002/cam4.7025adverse eventsatezolizumab plus bevacizumabesophagogastric variceal rupturehepatocellular carcinomaportal hypertension |
| spellingShingle | Takahiro Kinami Shinsuke Uchikawa Tomokazu Kawaoka Shintaro Yamasaki Masanari Kosaka Yusuke Johira Shigeki Yano Kei Amioka Kensuke Naruto Kenji Yamaoka Yasutoshi Fujii Hatsue Fujino Takashi Nakahara Atsushi Ono Eisuke Murakami Wataru Okamoto Masami Yamauchi Daiki Miki Masataka Tsuge Shiro Oka Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma Cancer Medicine adverse events atezolizumab plus bevacizumab esophagogastric variceal rupture hepatocellular carcinoma portal hypertension |
| title | Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma |
| title_full | Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma |
| title_fullStr | Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma |
| title_full_unstemmed | Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma |
| title_short | Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma |
| title_sort | efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma |
| topic | adverse events atezolizumab plus bevacizumab esophagogastric variceal rupture hepatocellular carcinoma portal hypertension |
| url | https://doi.org/10.1002/cam4.7025 |
| work_keys_str_mv | AT takahirokinami efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT shinsukeuchikawa efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT tomokazukawaoka efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT shintaroyamasaki efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT masanarikosaka efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT yusukejohira efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT shigekiyano efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT keiamioka efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT kensukenaruto efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT kenjiyamaoka efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT yasutoshifujii efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT hatsuefujino efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT takashinakahara efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT atsushiono efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT eisukemurakami efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT wataruokamoto efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT masamiyamauchi efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT daikimiki efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT masatakatsuge efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma AT shirooka efficacyandsafetyofatezolizumabplusbevacizumabinpatientswithportalhypertensionforunresectablehepatocellularcarcinoma |